Australia markets open in 6 hours 26 minutes

Cellectis S.A. (CMVLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
10.610.00 (0.00%)
As of 11:51AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close10.61
Open10.61
Bid0.00 x 0
Ask0.00 x 0
Day's range10.61 - 10.61
52-week range10.61 - 33.48
Volume200
Avg. volume16
Market cap482.344M
Beta (5Y monthly)2.22
PE ratio (TTM)N/A
EPS (TTM)-2.78
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

    NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases, announced today that pre-clinical data that support anti-tumor activity of UCARTMESO will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021), to be held in Washing

  • GlobeNewswire

    Monthly information on share capital and company voting rights

    (Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights09/30/202145,465,31051,066,417 About CellectisCellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-s

  • GlobeNewswire

    Cellectis Announces Participation in Five Investor Conferences

    NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for monogenic diseases, today announced that management plans to participate in five virtual investor conferences. 11th Annual Biotech Symposium (Goldman Sachs) Date: Tuesday, September 7, 2021Time: 8AM-6PM (GMT) Citi’s 16th